Steve Soper,
Foundation Distinguished Professor, Director, Center of BioModular Multi-Scale System for Precision Medicine,
The University of Kansas
Prof. Soper is currently a Foundation Distinguished Professor in Chemistry and Mechanical Engineering at the University of Kansas, Lawrence. Prof. Soper also holds an appointment at Ulsan National Institute of Science and Technology in Ulsan, South Korea, where he is a World Class University Professor. He is also serving as a Science Advisor for a number of major worldwide companies. Prof. Soper is currently on the Editorial Board for Scientific Reports and Journal of Micro- and Nanosystems.
As a result of his efforts, Prof. Soper has secured extramural funding totaling >$103M and has published over 265 peer-reviewed manuscripts (h index = 71) and is the author of 20 patents. He is also the founder of a startup company, BioFluidica, which is marketing devices for the isolation and enumeration of circulating tumor cells. His list of awards includes Chemical Instrumentation by the American Chemical Society, the Benedetti-Pichler Award for Microchemistry, Fellow of the AAAS, Fellow of Applied Spectroscopy, Fellow of the Royal Society of Chemistry, R&D 100 Award, Distinguished Masters Award at LSU and Outstanding Scientist/Engineer in the state of Louisiana in 2001. Finally, Prof. Soper has granted 60 PhDs and 6 MS degrees to students under his mentorship. He currently heads a group of 20 researchers.
Analysis of Rare Circulating Tumor Cells (CTCs) for the Management of Cancer-related Diseases
Wednesday, 30 September 2015 at 08:30
Add to Calendar ▼2015-09-30 08:30:002015-09-30 09:30:00Europe/LondonAnalysis of Rare Circulating Tumor Cells (CTCs) for the Management of Cancer-related DiseasesNGS, SCA, Mass Spec: The Road to Diagnostics in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Management of many cancer-related diseases is not restricted to diagnosis, but also must include prognosis, patient stratification, determining drug efficacy, and monitoring for disease recurrence. To assist clinicians in managing cancer diseases, the use of rare CTCs are seen as attractive biomarkers due to the minimally invasive nature of securing them (peripheral blood draw) and the wealth of material they contain (genomic DNA, messenger RNA, proteins, etc). We have developed an assay and the associated hardware that can select directly from peripheral blood CTCs of different types to assist in making clinical decisions for cancer patients in all phases of the management pipeline. Fluidic systems have been generated that can select with high efficiency multiple CTC types that provide complementary information, including those that have an epithelial phenotype and those that possess the ability to digest the extracellular matrix. CTCs of both types were enumerated in a variety of cancer diseases including breast, ovarian, colorectal and pancreatic. Molecular profiling of these rare cell types was also carried out such as mutation detection and mRNA expression profiling. The fluidic system could also be programmed using the appropriate selection antibodies to target circulating cells from non-solid tumors, for example acute myeloid leukemia (AML) and multiple myeloma that would obviate the need for bone marrow biopsies. In the case of multiple myeloma, CD138 was used to select circulating multiple myeloma cells and these cells could be analyzed via FISH to search for chromosome 13 deletions. For AML, the selected leukemic cells (selected using combinations of CD117, CD34 and CD33) could be secured from the fluidic system and immunophenotyped using a miniature flow cytometer. The molecular profiling of rare circulating tumor cells will be discussed with the prospects of performing such analyses on early stage disease, where the CTC abundance is significantly lower.
Add to Calendar ▼2015-09-28 00:00:002015-09-30 00:00:00Europe/LondonNGS, SCA, Mass Spec: The Road to DiagnosticsNGS, SCA, Mass Spec: The Road to Diagnostics in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2015-09-30 08:30:002015-09-30 09:30:00Europe/LondonAnalysis of Rare Circulating Tumor Cells (CTCs) for the Management of Cancer-related DiseasesNGS, SCA, Mass Spec: The Road to Diagnostics in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
